Drugs / TK001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03021785 | Oct 2017 → Nov 2018 | wet macular degeneration | Jiangsu T-Mab Biopharma Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT02613559 | Nov 2015 → Jun 2018 | wet macular degeneration | Jiangsu T-Mab Biopharma Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TK001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02613559 ↗ |
| Action | Inhibit | “anti-VEGF humanized monoclonal antibody injection” NCT03021785 ↗ |
| Modality | Monoclonal antibody | “TK001 is a full-length recombinant humanized anti-VEGF monoclonal antibody.” NCT02613559 ↗ |
| Route | Intravitreal | “single intravitreal injections of TK001” NCT02613559 ↗ |